Myeloproliferative disorders and its associated mutations
Authors
Abstract:
Myeloproliferative Neoplasm (MPN) are a clonal disorder in hematopoietic stem cells (HSC). MPN is categorized to 8 subclasses, including chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocytopenia (ET), primary myelofibrosis (PMF), systematic mastositosis (SM), chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia (CNL), and unclassified myelofibrosis disorders (UMPN). It usually occurs in 5th to 7th decade of life. However, CNL and ET have been observed in children. A lot of mutations have been identified in these disorders that Jak2V617F is the most important mutation. Moreover, several somatic mutations other than JAK2V617F in MPN patients have been reported. Such mutations include MPL, TET2, ASXL1, IDH1, IDH2, CBL, LNK, IKZF, and EZH2 from precursor stem cells. The role of mutations mentioned is not clear in pathogenesis of this disease. Hence, in this study, mutations in different stages of myeloproliferative disorders have been reviewed.
similar resources
Low Frequency of C-MPL Gene Mutations in Iranian Patients with Philadelphia-Negative Myeloproliferative Disorders
Background Myeloproliferative disorders are a group of diseases characterized by increased proliferation of myeloid lineage. In addition to JAK2V617F mutation, several mutations in the c-MPL gene were described in patients with Philadelphia-negative chronic myeloproliferative disorders that could be important in the pathogenesis of diseases. The aim of present study was to investigate the fre...
full textMutations and promoter methylation status of NPM1 in myeloproliferative disorders.
We determined mutations and promoter methylation status of NPM1 using pyrosequencing in 199 samples of myeloid neoplasia including myeloproliferative disorders (MPD). The mutations were present in 4% of chronic myelomonocytic leukemia, but not in other MPD or myelodysplastic syndromes. Promoter methylation was rare, and was found in only three samples of MPD.
full textDiagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders.
Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders Andreas Reiter,* David Grimwade,° Nicholas C.P. Cross *III. Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; °Department of Medical and Molecular Genetics, Guy’s, King’s and St. Thomas’ School of Medicine, Guy's Campus and Department...
full textNon-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
We studied non-driver mutations in 62 subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis upon diagnosis, including 45 subjects with primary myelofibrosis (PMF) and 17 with post-polycythemia vera or post-essential thrombocythemia myelofibrosis (post-PV/ET MF). Fifty-eight subjects had ≥1 non-driver mutation upon diagnosis. Mutations in mRNA splicing genes, especially in U2A...
full textChronic Myeloproliferative Disorders
JAK2, an acquired mutation of JAK2, is present in a majority of patients with polycythemia vera and to a lesser extent among patients with the other myeloproliferative disorders. We analyzed the effect of JAK2 on the expression of polycythemia rubra vera 1(PRV-1), using an in vitro model. Compared to wild-type JAK2, the presence of JAK2 increased both PRV-1 protein and mRNA levels in murine mye...
full textEosinophilic myeloproliferative disorders.
Despite recent attempts to define and classify patients with marked eosinophilia and features consistent with myeloproliferative disease, areas of controversy remain. These are particularly apparent in situations in which multiple lineages are involved in a clonal process and clinical manifestations are overlapping. Although the introduction of new molecular diagnostics and targeted therapies h...
full textMy Resources
Journal title
volume 2 issue 4
pages 3- 11
publication date 2014-11
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023